TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Documented EGFR mutation~* Documented c-MET dysregulation~* Prior clinical benefit on EGFR inhibitors and then subsequent progression~  -≥ 18 year old~* Life expectancy of ≥ 3 months~* ECOG performance status ≤ 2~Exclusion Criteria:~* Unable to swallow tables once or twice daily~* Previous treatment with c-MET inhibitor~* Any unresolved toxicity from previous anticancer therapy greater than grade 1~* History of cystic fibrosis~* History of acute or chronic pancreatitis~* Unable to undergo MRI or CT scans~* Known history of HIV~* Undergone a bone marrow or solid organ transplant~* Clinically significant wound or lung tumor lesions with increased likelihood of bleeding~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INC280 100 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 200 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 400 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 800 mg Cap QD Phase Ib (Type: EXPERIMENTAL): cap=capsule; QD=once daily
- INC280 200 mg Cap BID Phase Ib (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 400 mg Cap BID Phase Ib (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 600 mg Cap BID Phase Ib (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 200 mg Tab BID Phase Ib (Type: EXPERIMENTAL): tab=tablet; BID=twice daily
- INC280 400 mg Tab BID Phase Ib (Type: EXPERIMENTAL): tab=tablet; BID=twice daily
- INC280 400 mg Cap BID Phase II (Type: EXPERIMENTAL): cap=capsule; BID=twice daily
- INC280 400 mg Tab BID Phase II (Type: EXPERIMENTAL): tab=tablet; BID=twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Novel OPV2 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newborns at birth (range: 0-3 days of age).~* Mothers that consent for participation in the full length of the study.~* Mothers those are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Mother and newborns who are unable to participate in the full length of the study.~* A diagnosis or suspicion of immunodeficiency disorder either in the newborn or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate collection of blood by venipuncture.~* Acute diarrhea, infection or illness at the time of enrollment that would require admission to a hospital.~* Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit.~* Receipt of any polio vaccine (OPV or IPV) and Rotavirus Vaccine (RVV) before enrollment based upon documentation or mothers recall.~* Newborns from multiple births. Newborns from multiple births will be excluded to reduce the potential for contact transmission of vaccine poliovirus to siblings. The newborn from a multiple birth who is /are not enrolled would be likely to receive routine immunization and transmit vaccine poliovirus to the enrolled infant.~* Newborns from premature births (\<37 weeks of gestation).

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 3 Days
- Healthy Volunteers: t

Study Arms:
- Vaccine candidate arm (Type: ACTIVE_COMPARATOR): In this arm, participants will get nOPV2 vaccine candidate 1
- Placebo arm (Type: PLACEBO_COMPARATOR): In this arm, participants will get inactive substance like sucrose in BME media and buffer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B6 Effects for Women Taking Birth Control Pills

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy female subjects~* normal screening labs~* normal body weight~* nonpregnant~* Plasma PLP\<30nmol/L~Exclusion Criteria:~* history of gastrointestinal surgery~* chronic disease~* vitamin supplementation~* high protein diet~* progesterone~* no smoking~* chronic drug use~* alcoholism~* no vitamin supplementation

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin B6 Effects in OC Users (Type: EXPERIMENTAL): All subjects will be given an infusion of labeled serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.~The results from analysis of vitamin B6 and these amino acids in blood will provide us with specific measurements of the rates of two aspects of metabolism (Primary Outcomes 1 and 2) and specific measurements of vitamin B6 nutritional status (Primary Outcomes 3 and 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patient With Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients with chronic low back pain~Exclusion Criteria:~* Cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.~* Acute liver injury (such as hepatitis) or severe cirrhosis.~* Previous exposure to duloxetine.~* Body Mass Index (BMI) over 40.~* Major depressive disorder.~* Daily use of narcotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): Participants received duloxetine 60 milligram by mouth once daily for 12 weeks of double-blind treatment
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo by mouth once daily for 12 weeks of double-blind treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18;~* Patients who have undergone hematopoietic stem cell transplantation (HSCT);~* Patients who don't take any drug including Eltrombopag and rhTPO before hematopoietic stem cell transplantation (HSCT);~* Patients receiving either an autologous (Auto) or allogeneic (Allo) stem cell transplantation from a sibling,related donor, or matched unrelated donor are included;~* Agree to sign informed consent~Exclusion Criteria:~* Patients with thrombocytopenia causes by other reasons, such as drugs, cytomegalovirus or infection;~* Patients who had greater risk of thromboembolic disease within six months;~* Patients with a history of heart disease;~* Patients with severe organ dysfunction;~* Patients with other malignancies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Thrombopoietin- receptor (TPO-R) agonist
- rhTPO (Type: PLACEBO_COMPARATOR): Recombinant human thrombopoietin (rhTPO)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 65 years~* A documented diagnosis of major depressive disorder~Exclusion Criteria:~* Patients with a DSM IV Axis I disorder other than MDD within 6 months of enrolment~* Patients with a diagnosis of DSM IV Axis II disorder which has a major impact on the patient's current psychiatric status~* Patients whose current episode of depression exceeds 12 months or is less than 4 weeks prior to enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mycosis fungoides/Sézary syndrome~  * Stage IA-IVB disease~* Must have failed ≥ 1 prior topical treatment, including any of the following:~  * Steroids~ * Nitrogen mustard~ * Retinoids~ * Phototherapy~ * Photochemotherapy~ * Radiotherapy~ * Total skin electron beam~* Measurable disease with ≥ 1 indicator lesion designated prior to study entry~  * Erythrodermic patients are eligible~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* WBC ≥ 3,000/mm³~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 2.0 mg/dL~* Bilirubin ≤ 2.2 mg/dL~* AST and ALT ≤ 2 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile women must use effective double-method contraception for ≥ 4 weeks before, during, and for ≥ 4 weeks after completion of study therapy~* Fertile men must use effective contraception during and for ≥ 4 weeks after completion of study therapy~* No other malignancy within the past 5 years except treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, or surgically removed melanoma in situ of the skin (stage 0), with histologically confirmed free margins of excision and no current evidence of disease~* No acute infection requiring systemic treatment~* No known allergic reaction or hypersensitivity to thalidomide~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 weeks since prior topical therapy, systemic chemotherapy, or biological therapy~* No prior stem cell transplantation~* No other concurrent systemic antipsoriatic or anticancer therapies, including radiotherapy, thalidomide, or other investigational agents~* No other concurrent topical agents except emollients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active Rheumatoid Arthritis despite treatment with methotrexate~* Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening~* Having active disease at the time of screening and pre-infusion as defined by having at least 6 or more swollen joints and 6 or more tender joints~* Using methotrexate for at least 3 months prior to study enrollment~Exclusion Criteria:~* Patients having any systemic inflammatory condition~* Having Lyme disease or a rheumatic disease other than Rheumatoid Arthritis~* Who have used Disease-Modifying Antirheumatic Drugs (DMARDs) other than methotrexate within 4 weeks prior to screening~* Who have used corticosteroids within 4 weeks prior to screening~* Having received previous administration of infliximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
- Infliximab 3 mg/kg every 8 weeks (Type: EXPERIMENTAL): Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
- Infliximab 3 mg/kg every 4 weeks (Type: EXPERIMENTAL): Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
- Infliximab 10 mg/kg every 8 weeks (Type: EXPERIMENTAL): Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
- Infliximab 10 mg/kg every 4 weeks (Type: EXPERIMENTAL): Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects whose LDL-C is not controlled by a stable dose of atorvastatin (Population A).~* Subjects who are naïve to a treatment by lipid lowering drug and whose LDL-C is not controlled (Population B).~Exclusion Criteria:~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality.~* Pregnant females; breastfeeding females; males and females of childbearing potential; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception.~* Subjects who were administered or prior exposed to PF-04950615 and/or anti-body targeting PCSK9.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Population A (Type: EXPERIMENTAL): A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
- Population B (Type: EXPERIMENTAL): A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Age 20-35 yrs, and 60-80 yrs.~* 2. Ability to sign consent form (score \>23 on the 30-item Mini Mental State Examination, MMSE)~* 3. Stable body weight for at least 3 months~Exclusion Criteria:~* 1. Physical dependence or frailty (impairment in any of the Activities of Daily Living (ADL), history of falls (\>2/year) or significant weight loss in the past year)~* 2. Exercise training (\>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)~* 3. Pregnancy~* 4. Significant heart, liver, kidney, blood or respiratory disease~* 5. Peripheral vascular disease~* 6. Diabetes mellitus or other untreated endocrine disease~* 7. Active cancer~* 8. Use of nitrates~* 9. Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.~* 10. Alcohol or drug abuse~* 11. Severe depression (\>5 on the 15-item Geriatric Depression Scale, GDS)~* 12. Cardiac abnormalities such as a cardiac shunt or previously diagnosed pulmonary hypertension.~* 13. Systolic blood pressure \<100 or \>150, diastolic blood pressure \<60 or \>90.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- placebo sildenafil young (Type: PLACEBO_COMPARATOR): Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.
- sildenafil young (Type: EXPERIMENTAL): Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.
- placebo sildenafil older (Type: PLACEBO_COMPARATOR): Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.
- sildenafil older (Type: EXPERIMENTAL): Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* They are healthy infants based on medical history and clinical assessment.~* They are between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.~* Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.~Exclusion Criteria:~* Use of any investigational medicinal product prior to randomization.~* Previous vaccination against or infection with S. pneumoniae.~* History of anaphylactic shock or an allergic reaction to any prior vaccination.~* Any fever, illness (including malaria).~* Receipt of another vaccine within 30 days of study start.~* Chronic administration of an immunosuppressant or administration of immunoglobulins~* History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died of suddenly without apparent cause.~* History of meningitis, seizures or any neurological disorder.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- Pneumosil Lot 1 (Type: EXPERIMENTAL): Pneumosil Lot 1
- Pneumosil Lot 2 (Type: EXPERIMENTAL): Pneumosil Lot 2
- Pneumosil Lot 3 (Type: EXPERIMENTAL): Pneumosil Lot 3
- Synflorix (Type: ACTIVE_COMPARATOR): Synflorix

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~* Diagnosis of rheumatoid arthritis (RA) as defined by the 1987-revised American College of Rheumatology (ACR) criteria, with a disease duration less than 3 years, at least 8 swollen joints out of the 66 joints assessed, at least 10 tender joints out of the 68 joints assessed, at least 1 joint erosion or rheumatoid factor (RF) positivity, erythrocyte sedimentation rate (ESR) \>= 28 mm/1h or C-reactive protein (CRP) \>= 1.5 mg/dl~Exclusion Criteria:~* Chronic arthritis diagnosed before the age of 16~* Preceding treatment with MTX, cyclophosphamide, cyclosporin, azathioprine or more than 2 other disease-modifying anti-rheumatic drugs (DMARDs)~* Subject previously received anti-tumor necrosis factor (TNF) therapy~* Permanently wheelchair-bound or bedridden patients~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Female subject who is pregnant or breast-feeding or considering becoming pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.
- Adalimumab + methotrexate (Type: EXPERIMENTAL): Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
- Methotrexate (Type: EXPERIMENTAL): Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete